Keywords: fda, extends, tysabri, review, end, june, biotechnology

US FDA extends Tysabri review to end of June

Article | 27 March 2006

Print This

US biotechnology firm Biogen Idec and Irish drugmaker Elan Corp says that the Food and Drug Administration has informed them ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in